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Molecular Medicine SelectFrom Alzheimer’s disease and the obesity epidemic to the chronic health effects of certain viral infections, scientists
in academia and big pharma are seeking new therapeutic targets and strategies to tackle these diseases. However, as
discussed in this Molecular Medicine Select, designing more effective drugs with fewer side effects that fight the
disease itself and not just the symptoms requires a thorough understanding of the underlying mechanisms of disease
pathogenesis.An agonist of the BRS-3
receptor reduces food intake,
increases metabolic rate, and
induces weight loss in mice.
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Many molecular pathways, when disrupted, lead to obesity, resulting in a plethora of potential
therapeutic targets for treating this mushrooming epidemic. Out of this morass, a new player is
emerging thanks to molecular sleuthing by Guan et al. (2010). These investigators developed
a range of agonists and antagonists to bombesin receptor subtype-3 (BRS-3), a G protein-
coupled receptor expressed in the brain and implicated in energy metabolism but with an as
yet unknown physiological ligand. Treating a series of different mouse strains (either wild-
type animals or those lacking particular receptors or ligands involved in energy homeostasis)
with either a potent agonist (Bag-1) or antagonist (Bantag-1) of BRS-3, these investigators
now identify this receptor as an important new regulator of food intake and metabolism. Using
radiolabeled Bag-1, the researchers show that binding of this agonist to BRS-3 takes place
principally in the hypothalamus, a brain region that produces a number of different neuropep-
tides regulating food intake and energy metabolism. They then demonstrate that treating
healthy mice with Bag-1 resulted in reduced food intake, an increased metabolic rate, and
weight loss. This effect was not seen in mice lacking BRS-3, demonstrating that the agonist
was indeed mediating its effects via this receptor. Meanwhile, treatment of healthy rodents
with the BRS-3 antagonist, Bantag-1, resulted in increased food intake and weight gain.
Although the neurons that mediate the action of BRS-3 still need to be elucidated and the
natural ligand of BRS-3 identified, these findings suggest that agonists of BRS-3may be a valu-
able new class of antiobesity drug that could be used alone or in combination with other drugs
that target food intake and metabolic rate regulators such as leptin and neuropeptide Y.
X.-M. Guan et al. (2010). Cell Metab. Published online January 21, 2009. 10.1016/
j.cmet.2009.12.008.A miRaculous Target for Fighting HCV
The obesity epidemic may be in plain sight, but other epidemics such as that caused by the hepatitis C virus (HCV) are hidden
from view. More than 170 million people worldwide suffer from hepatitis C and are at risk for developing liver disease and
hepatocellular carcinoma. Although HCV infection can be treated, the current drug regimen (interferon-a and ribavirin) has
serious side effects and is only effective in 50% of patients. Taking a fresh approach to tackling the scourge of HCV, Lanford
et al. (2010) set out to deprive the virus of an essential host factor rather than targeting the virus itself. They homed in on a small
RNA expressed in liver cells called miR-122 that is essential for maintaining production of HCV RNA. Using an oligonucleotide
(modified to enhance stability and affinity) that targets the 50 end of miR-122, they tested whether this drug would block
production of HCV RNA in chimps with chronic HCV infection. The authors show that the oligonucleotide was able to
sequester miR-122, leading to suppression of HCV RNA levels by more than two orders of magnitude at the higher drug
dose. Continued suppression of HCV RNA resulted in downregulation of both interferon production and the expression of
interferon-regulated genes, suggesting that the host innate immune response normalized once HCV was under control.
The chimps were treated weekly with the drug for 12 weeks, leading to suppression of viremia that continued for months after
drug treatment was halted. Blood counts, blood chemistry, and urine analysis revealed that the drug was safe and well toler-
ated, and 19weeks after the start of treatment, animals in the high-dose group even showed an improvement in liver histology.
Another benefit of this oligonucleotide, the authors argue, is that HCV may have trouble developing resistance to this drug as
evidenced by the lack of adaptive mutations emerging in the two sites in the 50 noncoding region of the HCV genome that bind
to miR-122. Although preliminary, these encouraging findings in a primate model of hepatitis Cmay herald a new approach to
combating this common and debilitating disease.
R.E. Lanford et al. (2010). Science 327, 198–201.Surfing for New Antivirals
Another common viral infection with serious sequelae is caused by respiratory syncitial virus (RSV). RSV causes respiratory
tract infections that often require hospitalization, particularly among young children and the elderly, and there is no vaccine orCell 140, January 22, 2010 ª2010 Elsevier Inc. 167
effective antiviral drug treatment. Enter Numata et al. (2010), who turn to the body’s own natural defenses to develop a new
therapeutic for combating RSV. RSV is known to activate the host’s innate immune system by activating Toll-like receptor 4
and its interacting protein CD14, leading to production of the cytokines interleukin-6 (IL-6) and IL-8, and an inflammatory
response. This response helps to fight the virus but also results in lung tissue damage that facilitates infection with secondary
opportunistic pathogens. Numata and colleagues study lung surfactants—mixtures of phospholipids and proteins produced
by lung epithelia that facilitate the expansion of lung alveolae as they fill with air. These investigators noted that one particular
lung surfactant, the phospholipid palmitoyl-oleoyl-phosphatidylglycerol (POPG), could block the production of proinflamma-
tory cytokines. They set out to discover whether POPG might be of value in fighting RSV infection. They found that POPG
blocked production of IL-6 and IL-8 by RSV-infected bronchial epithelial cells in vitro, prevented RSV from inducing these cells
to form syncitia, and inhibited spread of the virus from cell to cell. But how does POPG mediate these effects? The authors
show that POPGbinds directly to RSV, preventing the virus from interactingwith its receptors (such as CD14) on the surface of
lung epithelial cells. These encouraging findings are all in vitro, but does POPG work in a live animal? The authors show that
intranasal administration of POPG together with RSV to mice dramatically reduced RSV infection of lung tissue and blocked
the inflammatory response. Future experiments will need to demonstrate that prophylactic administration of POPG prior to
RSV exposure prevents infection, and that intranasal POPG treatment after RSV infection reduces the severity of disease.
Although it is a long road to the clinic, POPG has several major advantages: it is chemically stable, cheap to produce, and
easy to administer; it is also naturally produced by the body, making an immune response unlikely.
M. Numata et al. (2010). Proc. Natl. Acad. Sci. USA 107, 320–325.Reducing both BACE-1 and g-secretase
rescues memory loss in an Alzheimer’s
mouse model, as shown by the water
maze swim test (left), compared to
reducing either protease alone (right).
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Chow.Two Drugs Are Better Than One
Alzheimer’s disease (AD) is characterized by the buildup of plaques composed of
toxic amyloid-b peptide in the brain, which results in neuronal death, memory loss,
and cognitive deficits. The only drugs currently available treat the symptoms of AD
but not the underlying disease mechanism. Drugs are being developed against two
new therapeutic targets—the proteases BACE-1 and g-secretase—that sequentially
cleave the amyloid precursor protein (APP) into smaller active amyloid-b peptides.
Given that both proteases are required to process APP, inhibitors of BACE-1 and
g-secretase should reduce amyloid-b peptide production and plaque accumulation.
Unfortunately, such inhibitors have proved highly toxic at the doses required to
reduce amyloid plaque burden as BACE-1 and g-secretase cleave not just APP but
many different precursor proteins. Chow et al. (2010) propose using low doses of
a BACE-1 inhibitor and a g-secretase inhibitor in combination to reduce amyloid
plaque accumulation while simultaneously avoiding the toxic side effects of these
protease inhibitors. To test the feasibility of this antiamyloid combination therapy, the investigators used genetic engineering
to make a mouse that produces lower than normal amounts of BACE-1 and g-secretase. They then crossed these mice with
animals carrying mutations in both APP and g-secretase (a well-established mouse model of AD) that accumulate amyloid
plaques as they age and show progressive cognitive deficits in classic memory tests. The resulting offspring of this cross
exhibited normal behaviors on a number of different tests, a typical life span, and none of the toxic effects seen when
BACE-1 and/or g-secretase are drastically reduced or completely absent. As the offspring aged, they showed only low levels
of amyloid plaque deposition and did not develop the memory loss seen in the AD mouse model. These results support the
authors’ notion that modest decreases in BACE-1 and g-secretase can slow plaque accumulation and cognitive decline while
avoiding the toxicity associated with a blockade of protease activity. This study paves the way for preclinical and clinical trials
of low-dose BACE-1 and g-secretase inhibitor combination therapy for the treatment of AD.
V.W. Chow et al. (2010). Science Translational Medicine 2, 13ra1.
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